Clinical results

Rhone-Poulenc Rorer

Product: Taxotere

Indication: Non-small cell lung and breast cancers

Following are the Taxotere data presented by Rhone-Poulenc Rorer Inc. to the Oncologic Drugs Advisory Committee last week:

Patients with non-small cell lung cancer (NSCLC) and breast cancer were treated with 100 mg/m
2 of Taxotere, given in a one-hour infusion every three weeks.